Kevin Ki-Wai Ho

Kevin Ki-Wai Ho

Auto-generated profile, based on publicly available information

Kevin Ki-Wai Ho

Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
YDYujie Deng
Yujie Deng
JLJinqiu Lu
Jinqiu Lu
WLWenling Li
Wenling Li
AWAiling Wu
Ailing Wu
XZXu Zhang
Xu Zhang
KMKinglun Kingston Mak
Kinglun Kingston Mak
Osteoarthritis is one of the leading causes of pain and disability in the aged population due to articular cartilage damage. This warrants investigation of signaling mechanisms that could protect cartilage from degeneration and degradation. Here we show in a murine model of experimental osteoarthritis that YAP activation by transgenic overexpression or by deletion of its upstream inhibitory kinases Mst1/2 preserves articular cartilage integrity, whereas deletion of YAP in chondrocytes promotes cartilage disruption. Our work shows that YAP is both necessary and sufficient for the maintenance of cartilage homeostasis in osteoarthritis. Mechanistically, inflammatory cytokines, such as TNFα or IL-1β, trigger YAP/TAZ degradation through TAK1-mediated phosphorylation. Furthermore, YAP directly interacts with TAK1 and attenuates NF-κB signaling by inhibiting substrate accessibility of TAK1. Our study establishes a reciprocal antagonism between Hippo-YAP/TAZ and NF-κB signaling in regulating the induction of matrix-degrading enzyme expression and cartilage degradation during osteoarthritis pathogenesis.

26 October 2020 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
Liangbin ZhouLiangbin Zhou
Liangbin Zhou
VGVan Osch Gjvm
Van Osch Gjvm
JMJos Malda
Jos Malda
MSMartin J. Stoddart
Martin J. Stoddart
YLYuxiao Lai
Yuxiao Lai
LQLing Qin
Ling Qin

1 April 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WTWenxue Tong
Wenxue Tong
YZYelin Zeng
Yelin Zeng
DCDick Ho Kiu Chow
Dick Ho Kiu Chow
WYWai Yeung
Wai Yeung
JXJiankun Xu
Jiankun Xu
KMKingston King-Lun Mak
Kingston King-Lun Mak
Objectives Wnt16 is implicated in bone fracture and bone mass accrual both in animals and humans. However, its functional roles and molecular mechanism in chondrocyte differentiation and osteoarthritis (OA) pathophysiology remain largely undefined. In this study, we analysed its mechanistic association and functional relationship in OA progression in chondrocyte lineage. Methods The role of Wnt16 during skeletal development was examined by Col2a1-Wnt16 transgenic mice and Wnt16fl/fl;Col2a1-Cre (Wnt16-cKO) mice. OA progression was assessed by micro-CT analysis and Osteoarthritis Research Society International score after anterior cruciate ligament transection (ACLT) surgery with Wnt16 manipulation by adenovirus intra-articular injection. The molecular mechanism was investigated in vitro using 3D chondrocyte pellet culture and biochemical analyses. Histological analysis was performed in mouse joints and human cartilage specimens. Results Wnt16 overexpression in chondrocytes in mice significantly inhibited chondrocyte hypertrophy during skeletal development. Wnt16 deficiency exaggerated OA progression, whereas intra-articular injection of Ad-Wnt16 markedly attenuated ACLT-induced OA. Cellular and molecular analyses showed that, instead of β-catenin and calcium pathways, Wnt16 activated the planar cell polarity (PCP) and JNK pathway by interacting mainly with AP2b1, and to a lesser extend Ror2 and CD146, and subsequently induced PTHrP expression through phosphor-Raptor mTORC1 pathway. Conclusions Our findings indicate that Wnt16 activates PCP/JNK and crosstalks with mTORC1-PTHrP pathway to inhibit chondrocyte hypertrophy. Our preclinical study suggests that Wnt16 may be a potential therapeutic target for OA treatment.

1 April 2017 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
LKLing Kong
Ling Kong
LZLi-Zhen Zheng
Li-Zhen Zheng
LQLing Qin
Ling Qin
KHKevin K.W. Ho
Kevin K.W. Ho
As the most common form of joint disorder, osteoarthritis (OA) imposes a tremendous burden on health care systems worldwide. Without effective cure, OA represents a unique opportunity for innovation in therapeutic development. In contrast to traditional treatments based on drugs, proteins, or antibodies, stem cells are poised to revolutionize medicine as they possess the capacity to replace and repair tissues and organs such as osteoarthritic joints. Among different types of stem cells, mesenchymal stem cells (MSCs) are of mesoderm origin and have been shown to generate cells for tissues of the mesoderm lineage, thus, raising the hope for them being used to treat diseases such as OA. However, given their ability to differentiate into other cell types, MSCs have also been tested in treating a myriad of conditions from diabetes to Parkinson's disease, apparently of the ectoderm and endoderm lineages. There are ongoing debates whether MSCs can differentiate into lineages outside of the mesoderm and consequently their effectiveness in treating conditions from the ectoderm and endoderm lineages. In this review, we discuss the developmental origin of MSCs, their differentiation potential and immunomodulatory effects, as well as their applications in treating OA. We suggest further investigations into new therapies or combination therapies that may provide more effective treatment for bone and joint diseases. Furthermore, cell-based therapy and its associated safety and effectiveness should be carefully evaluated before clinical translation. This review provides updated information on recent approval of clinical trials and related applications of MSCs, and discusses additional efforts on cell-based therapy for treating OA and other joint and bone diseases.

1 November 2018 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
RCRoy Cheung
Roy Cheung
KHK.K.W. Ho
K.K.W. Ho
IAI.P.H. Au
I.P.H. Au
Winko W. AnWinko W. An
Winko W. An
JZJanet Hanwen Zhang-Lea
Janet Hanwen Zhang-Lea
MRM.J. Rainbow
M.J. Rainbow

1 May 2021 in Bioactive Materials
Verified
Journal Article
Open access
HYHao Yao
Hao Yao
JXJiankun Xu
Jiankun Xu
JWJiali Wang
Jiali Wang
YZYifeng Zhang
Yifeng Zhang
NZNianye Zheng
Nianye Zheng
LQLing Qin
Ling Qin
We previously demonstrated that magnesium ions (Mg2+) was a novel therapeutic alternative for osteoarthritis (OA) through promoting the hypoxia inducible factor-1α (HIF-1α)-mediated cartilage matrix synthesis. However, oxidative stress can inhibit the expression of HIF-1α, amplify the inflammation that potentially impairs the therapeutic efficacy of Mg2+ in OA. Vitamin (VC), a potent antioxidant, may enhance the efficacy of Mg2+ in OA treatment. This study aims to investigate the efficacy of combination of Mg2+ and VC on alleviating joint destruction and pain in OA. Anterior cruciate ligament transection with partial medial meniscectomy induced mice OA model were randomly received intra-articular injection of either saline, MgCl2 (0.5 mol/L), VC (3 mg/ml) or MgCl2 (0.5 mol/L) plus VC (3 mg/ml) at week 2 post-operation, twice weekly, for 2 weeks. Joint pain and pathological changes were assessed by gait analysis, histology, western blotting and micro-CT. Mg2+ and VC showed additive effects to significantly alleviate the joint destruction and pain. The efficacy of this combined therapy could sustain for 3 months after the last injection. We demonstrated that VC enhanced the promotive effect of Mg2+ on HIF-1α expression in cartilage. Additionally, combination of Mg2+ and VC markedly promoted the M2 polarization of macrophages in synovium. Furthermore, combination of Mg2+ and VC inhibited osteophyte formation and expressions of pain-related neuropeptides. Intra-articular administration of Mg2+ and VC additively alleviates joint destruction and pain in OA. Our current formulation may be a cost-effective alternative treatment for OA.